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A Critical Role for Stat3 Signaling
in Immune Tolerance
et al. (2002) have recently demonstrated that CD11c,
CD8 DCs, a subset previously implicated in cross-
priming (den Haan et al., 2000), could also induce periph-
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Signal transducer and activators of transcription
(Stats) are cytoplasmic transcription factors that are keyAntigen-presenting cells (APCs) can induce T cell acti-
vation as well as T cell tolerance. The molecular mech- mediators of cytokine and growth factor signaling path-
ways (Darnell, 1997). Recently, one of the members ofanisms by which APCs regulate this critical decision
of the immune system are not well understood. Here the Stat family, Stat3, has emerged as a negative regula-
tor of inflammatory responses. Indeed, Hackenmiller etwe show that Stat3 signaling plays a critical role in the
induction of antigen-specific T cell tolerance. Targeted al. have demonstrated that increased Stat3 activation in
c-fes/ mice is associated with impaired inflammatorydisruption of Stat3 signaling in APCs resulted in prim-
ing of antigen-specific CD4 T cells in response to an responses (Hackenmiller et al., 2000). Conversely,
Takeda et al. have found that in mice with a cell type-otherwise tolerogenic stimulus in vivo. Furthermore,
APCs devoid of Stat3 effectively break antigen-spe- specific disruption of the Stat3 gene in macrophages,
these cells are abnormally activated and produce highercific T cell anergy in vitro. Conversely, increased Stat3
activity in APCs led to impaired antigen-specific T cell levels of inflammatory cytokines in response to endo-
toxin (Takeda et al., 1999). Further highlighting the regu-responses. Stat3 signaling provides, therefore, a novel
molecular target for manipulation of immune activa- latory role of Stat3 signaling in immune responses, Welte
et al. have demonstrated that tissue-specific disruptiontion/tolerance, a central decision with profound impli-
cations in autoimmunity, transplantation, and cancer of this signaling pathway during hematopoiesis is asso-
ciated with an overactivated innate immunity leadingimmunotherapy.
to severe inflammatory bowel disease and lethality in
mutant mice (Welte et al., 2003).Introduction
In this study, we evaluated, therefore, whether Stat3
signaling may play a role in the ability of APCs to deter-Bone marrow (BM)-derived APCs play an important role
in the initiation of productive antigen-specific T cell re- mine T cell activation versus T cell tolerance. Indeed,
disruption of this signaling pathway leads to the genera-sponses (Banchereau and Steinman, 1998). However,
these cells are also required for the induction of T cell tion of APCs that effectively prime naive antigen-specific
T cells and restore the responsiveness of anergic CD4tolerance (Adler et al., 1998; Kurts et al., 1997). Thus,
APCs are at the center of a critical decision leading to T cells. Conversely, increased Stat3 activity in APCs
resulted in impaired T cell responses. Importantly, ourimmune activation versus immune tolerance. A potential
explanation for this dual function of APCs is that perhaps findings that induction of T cell tolerance occurs in mice
with an intact Stat3 signaling in APCs, but not in micea subset of APCs could preferentially induce tolerance
(Huang et al., 2000; Munn et al., 2002; Scheinecker et with targeted disruption of this signaling pathway, fur-
ther emphasizes an important regulatory role for Stat3 inal., 2002) while a different subpopulation may trigger
T cell priming. Alternatively, it has been proposed that the in vivo induction of antigen-specific T cell tolerance.
the state of activation/differentiation of the APC at the
time of antigen presentation is the central determinant Results
of T cell priming versus tolerance (Lanzavecchia, 1998),
and perhaps each APC’s subpopulation may have the Enhanced Antigen-Presenting Cell Function
potential to induce either T cell outcome. Indeed, Belz of Tyrphostin AG490-Treated Macrophages
To assess whether Stat3 signaling in APCs may influ-
ence antigen-specific T cell responses, we first treated*Correspondence: sotomed@moffitt.usf.edu
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peritoneal elicited macrophages (PEM) with increasing suggests that AG490-treated PEM are capable of over-
concentrations of the JAK-selective inhibitor, tyrphostin coming T cell unresponsiveness rather than just enhanc-
AG490, a compound known to block Stat3 activation in ing the activation of those naive T cells that may have
malignant cells (Catlett-Falcone et al., 1999). Following escaped tolerance induction in vivo.
this treatment, naive CD4 T cells specific for a MHC The ability of tyrphostin AG490 to enhance the anti-
class II-restricted epitope of influenza hemagglutinin gen-presenting capabilities of PEM was associated with
(HA) were added to these APCs and stimulated or not a complete inhibition of Stat3 DNA binding activity in
with cognate HA-peptide. As shown in Figure 1A, clono- these cells. Shown in Figure 1D is the Stat3 DNA binding
typic T cells encountering cognate peptide on AG490- activity of untreated or treated PEM. Untreated PEM
treated PEM display an enhanced HA-specific prolifera- display constitutive activation of Stat3. Following stimu-
tion (Figure 1Aa) and IL-2 production (Figure 1Ab) as lation with LPS, Stat3 activity was enhanced in PEM,
compared to T cells encountering cognate peptide on reminiscent of previous studies in human monocytic
either untreated PEM (No LPS) or PEM treated with LPS cells (Benkhart et al., 2000). In sharp contrast, PEM
alone. More importantly, AG490-treated PEM trigger ef- treated with LPS in the presence of 50 M of AG490
fector function of clonotypic CD4T cells, as determined display almost complete inhibition of Stat3 DNA binding
by the capacity of these T cells to produce IFN- in (Figure 1D, AG490/LPS), an effect that correlates with
response to HA-peptide stimulation (Figure 1Ac). In the ability of these APCs to restore the responsiveness
sharp contrast, antigen-specific T cells encountering of tolerant CD4 T cells (Figure 1C). Treatment of PEM
HA-peptide on untreated or LPS-treated PEM were un- with lower doses of AG490 also resulted in inhibition of
able to produce IFN-. This ability of AG490-treated Stat3 DNA binding activity, although this effect was not
PEM to trigger IFN- production was not just the result as dramatic as with the 50 M dose (see Supplemental
of the drug speeding up cytokine expression in naive Data at http://www.immunity.com/cgi/content/full/19/3/
T cells since kinetic studies showed that even after 72 425/DC1).
hr of incubation, T cells encountering HA-peptide on
untreated PEM were still unable to produce IFN- (Fig- Inhibition of Stat3 Signaling in Dendritic Cells
ure 1B). Restores the Responsiveness
Utilizing a T cell receptor transgenic model, we have of Tolerant CD4 T Cells
previously demonstrated that CD4 T cells specific for Given our results with PEM, we evaluated next whether
an MHC class II epitope of influenza hemagglutinin (HA) inhibition of Stat3 signaling in BM-derived DCs may also
are rendered unresponsive during the progression of influence the ability of these cells to present cognate
A20 B cell lymphoma expressing HA as a model tumor antigen to naive (Figure 2A) or tolerant T cells (Figure
antigen (A20HA) (Staveley-O’Carroll et al., 1998). In this 2B). Analysis of CD4 T cell responses to HA-peptide
system, clonotype-positive T cells were found to be presented by untreated or LPS-treated DCs showed that
tolerant by their failure to be primed in vivo as well these APCs can induce full activation of naive T cells,
as by their diminished proliferation and IL-2 and IFN- as determined by their capacity to proliferate and pro-
production in response to in vitro restimulation with cog-
duce IL-2 as well as IFN- (Figures 2Aa–2Ac, No LPS
nate antigen. However, as shown in Figure 1C, incuba-
or LPS). In contrast with our observations in PEM treated
tion of these same tolerant T cells (reisolated from
with LPS  AG490 (Figure 1A), similar treatment of BM-
A20HA lymphoma-bearing mice) with AG490-treated
derived DCs did not result in further enhancement of
PEM resulted in restoration of T cell responsiveness to
either HA-specific proliferation (Figure 2Aa) or IL-2 pro-cognate HA antigen. Indeed, PEM treated with either
duction (Figure 2Ab) by naive T cells. A modest increase16.6 or 50 M of AG490  LPS were able to trigger HA-
in IFN- production was observed, however, when naivespecific proliferation (Figure 1Ca), IL-2 (Figure 1Cb), and
T cells encountered HA-antigen on DCs treated withIFN- production by tolerant CD4 T cells (Figure 1Cc).
LPS  50 M of AG490 as compared to those T cellsIn sharp contrast, tolerant T cells encountering HA anti-
encountering antigen on DCs treated with LPS alonegen on either untreated (No LPS) or LPS-treated PEM
(Figure 2Ac).remained fully unresponsive.
Analysis of the response of tolerant CD4 T cells toStrikingly, tolerized T cells display an enhanced anti-
cognate antigen presented by BM-derived DCs, how-gen-specific proliferation and produce significantly
ever, unveiled important findings (Figure 2B). First, un-more IL-2 and IFN- on a per cell basis than naive anti-
treated or LPS-treated BM-derived DCs were unable togen-specific T cells in response to antigen presented
restore the responsiveness of tolerant T cells isolatedby AG490-treated PEM. Indeed, HA-specific prolifera-
from tumor-bearing mice. Although tolerant T cells weretion by tolerized T cells was almost 8-fold higher relative
capable of proliferating in response to HA-peptide (Fig-to the response of naive T cells to cognate antigen pre-
ure 2Ba, No LPS or LPS), this response was of a lessersented by PEM treated with LPS  50 M of AG490
magnitude relative to the proliferative response of naive(3283 cpm versus 425 cpm per 100 clonotype T cells,
T cells encountering antigen on untreated or LPS-respectively, Figures 1Ca and 1Aa). A 10-fold increase
treated DCs (Figure 2Aa, No LPS or LPS). Furthermore,in IFN- production by tolerized T cells relative to naive
tolerant T cells were unable to produce IL-2 (Figure 2Bb)T cells was also observed (37.8 pg/ml versus 3.7 pg/ml
or IFN- (Figure 2Bc) in response to cognate antigenper 100 clonotype T cells respectively, Figures 1Cc
presented by untreated or LPS-treated DCs. Only whenand 1Ac). IL-2 production by tolerized T cells was also
DCs were treated with LPS plus AG490 were they capa-increased, but only by 2-fold as compared to naive clo-
ble of restoring the responsiveness of tolerant T cells.notypic T cells (21.7 pg/ml versus 10 pg/ml, respectively,
Indeed, in these tolerant T cells, HA-specific prolifera-Figures 1Ab and 1Cb). This greater magnitude of re-
sponse of tumor-tolerant T cells than that of naive T cells tion was no longer inhibited (Figure 2Ba), and they re-
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Figure 1. Antigen-Specific CD4 T Cell Responses to Cognate Antigen Presented by AG490-Treated PEM
(A) PEM from BALB/c mice (1  105/well) were cultured for 48 hr in media alone (No LPS), LPS (5 g/ml), or LPS AG490 (0–50 M). Then,
supernatants were collected, and 5  104 purified naive CD4 T cells from the spleen of anti-HA TCR mice were added to PEM in the presence
or not of 12.5 g of HA peptide. (a) [3H]thymidine incorporation was determined after 3 days in culture. Values represent the mean  SE of
the cpm per 100 clonotype T cells per well. In a parallel plate, IL-2 (b) and IFN- production (c) by antigen-specific T cells was determined
by ELISA. Data represent mean  SE of triplicate cultures and are expressed as the amount of cytokine produced per 100 clonotype T cells.
Shown is a representative experiment of four independent experiments with similar results.
(B) Kinetics of IFN- production by AG490-treated PEM. Naive CD4 T cells were cultured with PEM treated with LPS or LPS  AG490 in the
presence or not of HA-peptide. Supernatants were collected and IFN- production was determined by ELISA.
(C) PEM (1  105/well) were cultured with 5  104 CD4 T cells isolated from the spleen of A20HA-bearing mice in the presence or not of HA-
peptide. (a) HA-specific proliferation, (b) IL-2 production, and (c) IFN- production by 100 clonotype T cells. Shown is a representative
experiment of four independent experiments with similar results.
(D) Nuclear extracts from PEM were isolated and Stat3 activity was determined by EMSA. Nuclear extracts from EGF receptor-expressing
NIH3T3 cells stimulated with EGF were used as positive control.
Immunity
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Figure 2. CD4 T Cell Responses to Cognate Antigen Presented by AG490-Treated DCs
(A) BM-derived DCs (1  104/well) were cultured for 48 hr in media alone (No LPS), LPS (5 g/ml), or LPS AG490 as indicated. Then, 5 
104 purified naive anti-HA CD4 T cells were added in the presence or not of 12.5 g of HA peptide. (a) HA-specific proliferation, (b) IL-2
production, and (c) IFN- production by 100 clonotype T cells.
(B) BM-derived DCs (1  104/well) were cultured as above with 5  104 purified CD4 T cells from the spleen of A20HA-bearing mice in the
presence or not of 12.5 g of HA peptide. (a) HA-specific proliferation, (b) IL-2 production, and (c) IFN- production. Data are representative
of two independent experiments with similar results.
gained the ability to produce IL-2 (Figure 2Bb) and IFN- 3A, PEM treated with IL-10 display significantly higher
Stat3 activity as compared to untreated PEM. This in-(Figure 2Bc) in response to cognate peptide. The ability
of tolerized antigen-specific T cells to produce signifi- creased Stat3 activity was associated with impairment
in their T cell stimulatory capabilities, since clonotypiccantly more IL-2 and IFN- on a per cell basis than naive
T cells encountering cognate peptide on these APCsantigen-specific T cells (Figures 2B versus 2A) suggests
produce less IL-2 than those T cells encountering anti-again that treatment of APCs with AG490 renders them
gen on untreated PEM (Figure 3B). Additional supportcapable of overcoming T cell unresponsiveness.
for a regulatory role of Stat3 signaling in APC function
was provided by the assessment of the T cell stimulatory
Increased Stat3 Activity in APCs Resulted in Impaired capabilities of DCs transiently transfected with Stat3c,
Antigen-Specific T Cell Responses a mutant form of Stat3 that is constitutively activated
Previous studies have shown that Stat3 is tyrosine phos- without tyrosine phosphorylation (Bromberg et al.,
phorylated in response to stimulation with IL-10 (Fin- 1999). As shown in Figure 3C, nontransfected or empty
vector-transfected DC cell line 2.4 (DC 2.4) efficientlybloom and Winestock, 1995). Indeed, as shown in Figure
Stat3 Signaling and Immune Tolerance
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tant mice (H-2b), we assessed the ability of their PEM
to present ovalbumin (OVA) peptide to transgenic CD4
T cells expressing an  TCR specific for OVA (Barnden
et al., 1998). As shown in Figure 4A, anti-OVA CD4
T cells encountering cognate antigen on LPS-stimulated
PEM from LysMcre/Stat3flox/ (Stat3/ PEM) produced
higher levels of IL-2 (Figure 4Aa) and IFN- (Figure 4Ab)
than those antigen-specific T cells encountering OVA-
peptide on PEM from C57BL/6 mice (Stat3/) or lit-
termate LysMCre/Stat3flox/. It should be pointed out that
the ability of Stat3/ PEM to efficiently prime T cell
responses was not the result of potential minor genetic
differences between OT-II mice and LysMcre/Stat3flox/
mice, since no cytokine production was detected in the
absence of OVA peptide stimulation (data not shown).
PEM devoid of Stat3 were also able to restore the
responsiveness of tolerant CD4 T cells from tumor-
bearing mice. As shown in Figure 4B, anti-OVA CD4
T cells reisolated from animals harboring an OVA-
expressing melanoma tumor (B16-OVA) were found to
be tolerant by their lack of IL-2 (Figure 4Ba) and IFN-
production (Figure 4Bb) in response to OVA-peptide pre-
sented by syngeneic PEM. Similarly, tolerant T cells re-
mained unresponsive to stimulation with cognate anti-
gen presented by LPS-stimulated PEM from littermate
controls. In sharp contrast, presentation of OVA-peptide
by LPS-stimulated PEM from Stat3/ mice resulted in
restoration of responsiveness of tolerant T cells as de-
termined by the ability of these cells to produce signifi-
cant levels of IL-2 and IFN-. Similar to our findings
with AG490-treated APCs, tolerized T cells encountering
cognate antigen on Stat3/ PEM produce significantly
more IL-2 and IFN- on a per cell basis than naive anti-
Figure 3. CD4 T Cell Responses to Antigen Presented by APCs gen-specific T cells (Figure 4B versus 4A). Therefore,
with Increased Stat3 Activity Stat3/ PEM seem to be capable of reversing T cell
(A) Stat3 binding activity was determined by EMSA of nuclear ex- unresponsiveness rather than just enhancing the activa-
tracts from untreated or PEM treated with IL-10 (10 ng/ml) for 24
tion of those T cells that may have escaped tolerancehr.
induction in vivo.(B) PEM (1  105/well) were cultured for 24 hr in media alone or IL-
EMSA of nuclear extracts isolated from aliquots of10 as indicated. Then, supernatants were discarded, and 5  104
naive anti-HA CD4 T cells were added in the presence or not of Stat 3/PEM and control PEM used in the above experi-
12.5 g of HA peptide. After 48 hr, IL-2 production was determined ments are shown in Figure 4C. As expected, PEM from
by ELISA. Data is representative of three independent experiments mutant mice lack activated Stat3 as compared to PEM
with similar results.
isolated from control mice. Interestingly, this lack of(C) DC 2.4 cells were transfected with either pcDNA3 empty vector
Stat3 activity in PEM from LysMcre/Stat3flox/ mice wasor Stat3c expression vector. Then, 1  104 DCs were incubated with
associated with an increased activity of the proinflam-5  104 purified anti-OVA transgenic CD4 T cells in the presence
(or not) of 3 g/ml of OVA peptide. Forty-eight hours later, IL-2 matory Stat1 signaling pathway (Figure 4C, Stat 1:1).
production was determined by ELISA. Values represent mean  SE
of triplicate cultures and are representative of two independent Injection of a Tolerogenic Dose of Peptide Ledexperiments.
to Antigen-Specific T Cell Activation Rather
Than T Cell Tolerance in Mice with Targeted
Disruption of Stat3 Signalingtriggers IL-2 production by CD4 T cells. In contrast,
antigen presentation by DC 2.4 cells transfected with In a well-characterized model of high dose peptide-
induced antigen-specific T cell tolerance (Kearney et al.,Stat3c led to diminished IL-2 production by antigen-
specific T cells rather than effective T cell priming. 1994), we determined next whether Stat3 signaling may
play a role in the in vivo induction of T cell tolerance.
Naive HA-specific CD4 T cells were transferred intoPEM with Genetic Disruption of Stat3 Efficiently Prime
Naive Antigen-Specific T Cells and Restore LysMcre/Stat3flox/ mutant mice or littermate LysMCre/
Stat3flox/ (backcrossed to H-2d background) as well asthe Responsiveness of Tolerant T Cells
Given the above results, we asked next whether macro- into BALB/c control mice. Two days later, mice were
injected i.v. with a tolerogenic dose of HA-peptide, andphages genetically devoid of Stat3 (Takeda et al., 1999)
can effectively prime naive antigen-specific T cells 2 weeks later animals were sacrificed and antigen-spe-
cific T cell responses were analyzed. Although no signifi-and/or restore the responsiveness of tolerized T cells.
Because of the background of LysMcre/Stat3flox/ mu- cant differences in the percent of clonotype CD4
Immunity
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Figure 4. Antigen-Specific CD4 T Cell Responses to Cognate Antigen Presented by Stat3/ PEM
(A) PEM (1  105/well) from C57BL/6, LysMCre/Stat3flox/ (littermate), or LysMcre/Stat3flox/ mutant mice (Stat3/) were treated with 5 g/ml
of LPS and incubated with 5  104 purified anti-OVA CD4 T cells in the presence of 3 g/ml of OVA peptide. Twenty-four hours later,
supernatants were collected and assayed for IL-2 (a) or IFN- production (b) by ELISA.
(B) PEM from the mice described in (A) were cultured with 5  104 CD4 T cells isolated from B16-OVA-bearing mice. Twenty-four hours later,
supernatants were collected and assayed for IL-2 (a) and IFN- (b) by ELISA. Data represent mean SE of triplicate cultures and are expressed
as the amount of cytokine produced per 100 OT-II transgenic T cells. Shown is a representative experiment of three independent experiments
with similar results.
(C) EMSA of nuclear extracts from PEM used in (B).
T cells was observed in the spleen of either untreated (Figure 5B, black bars). However, this response was
absent in T cells isolated from BALB/c mice or littermate(black bars) or in vivo HA peptide-treated (stippled bar)
BALB/c mice (Stat3/), littermate controls, or LysMcre/ control mice that received a single i.v. injection of high
dose peptide (Figure 5B, stippled bars), indicative thatStat3flox/ mutant mice (Stat 3/) (Figure 5A), functional
analysis of T cells from these mice showed striking dif- these antigen-specific T cells were rendered tolerant in
vivo. Although T cells reisolated from untreated lit-ferences. Antigen-specific CD4 T cells isolated from
untreated BALB/c mice or littermate controls produce termate controls produce low amounts of IFN- in re-
sponse to HA-peptide (Figure 5C, black bar, littermate),IL-2 in response to in vitro stimulation with HA-peptide
Stat3 Signaling and Immune Tolerance
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Stat3/ mice were still capable of producing significant
amounts of IL-2 in response to cognate peptide (Figure
5B, stippled bars). More importantly, these same CD4
T cells produce significant levels of IFN- upon restimu-
lation with cognate peptide in vitro (Figure 5C, stippled
bar), indicative that they were primed in vivo in response
to an otherwise tolerogenic dose of peptide.
Disruption of Stat3 Signaling Pathway Leads
to the Generation of Inflammatory APCs
To elucidate the mechanism(s) by which macrophages
devoid of Stat3 induce priming rather than tolerance of
antigen-specific T cells, we evaluated next the pheno-
typic characteristics and the cytokine/chemokine profile
of these APCs. Freshly isolated PEM from Stat3/ mice
display an increased expression of MHC class II mole-
cules as well as B7.1 and B7.2 costimulatory molecules
relative to PEM from control mice (Figure 6A). In spite
of these phenotypic changes, no constitutive expression
of inflammatory mediators was observed in PEM from
mutant mice (Figure 6B, LPS). Following stimulation
with LPS, no further changes in the expression of MHC
class II molecules or costimulatory molecules were ob-
served in either PEM from mutant mice or control mice
(data not shown). However, LPS-stimulated PEM from
Stat3/ mice display significantly higher mRNA levels
of the chemokines RANTES, MIP-1, MIP-1, MIP-2, IP-
10, and the cytokine IL-6 as compared to LPS-stimu-
lated PEM from control mice (Figure 6B). In addition, IL-
12 mRNA (Figure 6B) as well as IL-12 protein (Figure
6C) was detected in LPS-stimulated Stat3/ PEM at
the time that no IL-12 mRNA or protein could yet be
detected in control PEM. Importantly, no IL-10 was de-
tected in the supernatants of LPS-stimulated Stat3/
Figure 5. Effect of Disruption of Stat3 Signaling on the In Vivo Re- PEM, cytokine that was clearly present in the superna-
sponse to High Dose HA-Peptide
tants of Stat3/ PEM controls (Figure 6D).
LysMcre/Stat3flox/ mutant mice, LysMCre/Stat3flox/ littermate, or
BALB/c mice received 2.5  106 anti-HA TCR transgenic CD4T
Supernatants from Stat3/ PEM Restorecells i.v. Two days later half the mice received HA-peptide (275 g/
i.v.) (stippled bars) or vehicle alone (black bars) given i.v. Animals the Responsiveness of Tolerant
were sacrificed 2 weeks later, and T cells were purified from their Antigen-Specific CD4 T Cells
spleens. Next, to determine the potential contribution of soluble
(A) Two-color flow cytometry staining for CD4 versus anti-HA TCR inflammatory mediator(s) in the ability of PEM from
clonotype. Data represent mean  SE of the percentage of T cells
Stat3/ mice to influence T cell responses, we trans-coexpressing CD4 and the clonotypic TCR for four mice/group.
ferred supernatants from LPS-stimulated Stat3/ PEMPurified T cells were also stimulated with HA-peptide plus fresh
splenocytes for 48 hr. Supernatants were collected and assayed for into tolerant T cells cultured with syngeneic PEM and
IL-2 (B) and IFN- production (C) by ELISA. Data represent mean  cognate peptide. Tolerized T cells were obtained from
SE of triplicate cultures from three mice in each group. Data are two well-characterized models of tolerance induction:
representative of two independent experiments with similar results. antigen-specific CD4 transgenic T cells rendered aner-
gic during tumor progression (Staveley-O’Carroll et al.,
1998) and CD4 T cell clones (AE.7 clone) renderedthis response was also blunted in T cells isolated from
littermate controls treated with a tolerogenic dose of tolerant in vitro by stimulation with anti-CD3 antibodies
in the absence of costimulation (Jenkins et al., 1990).peptide (Figure 5C, stippled bar). Therefore, antigen-
specific T cells from either BALB/c mice or littermate As shown in Figure 7A, transfer of supernatant from
LPS-stimulated Stat3/ PEM, but not supernatantscontrols were rendered fully tolerant following injection
of high dose HA-peptide in vivo. In sharp contrast, induc- from controls, restores the responsiveness of tolerant
T cells isolated from tumor-bearing mice as determinedtion of antigen-specific CD4 T cell tolerance was not
observed in mice with a targeted disruption of Stat3. As by the ability of these T cells to produce significant levels
of IFN-. Of note, the magnitude of IFN- production byseen in Figure 5B (black bars), antigen-specific CD4
T cells isolated from untreated Stat3/ mice produce these tolerant T cells was similar to that of naive T cells
primed in vivo with recombinant vaccinia-encoding HAsimilar amounts of IL-2 as T cells from either BALB/c or
littermate controls in response to restimulation with HA- (data not shown). Tolerized AE.7 T cells also regain their
ability to produce IL-2 in response to cognate antigenpeptide. But, unlike T cells isolated from HA-treated
control mice, CD4 T cells from in vivo HA-treated only when supernatants from Stat3/ PEM were added
Immunity
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Figure 6. Phenotypic and Functional Characteristics of Stat3/ PEM
(A) Freshly isolated PEM from either C57BL/6, littermate, or LysMcre/Stat3flox/ mutant mice were stained for the expression of I-Ab, B7.1, and
B7.2. Open histogram in each figure represents staining with isotype antibody. Data is representative of two independent experiments. (B)
PEM from the mice in (A) were treated or not with LPS (5 g/ml) for 24 hr. Then total RNA was isolated and RPA was performed. In a parallel
culture, supernatants were collected and the production of IL-12 (C) and IL-10 (D) was determined by ELISA. Data represent mean  SE of
triplicate cultures and are representative of two independent experiments.
to the cultures (Figure 7B, Stat3/). However, the mag- priming (Huang et al., 1994) or tolerance induction (Adler
et al., 1998; Kurts et al., 1997; Sotomayor et al., 2001).nitude of this recovery was approximately 50% relative
to the levels of IL-2 produced by nontolerized AE.7 In this study we have unambiguously identified Stat3
signaling in APCs as a critical pathway influencing theT cells (Figure 7B, Control).
In order to identify the putative factor(s) responsible functional outcome of antigen-specific T cells. Further-
more, we have found that in mice lacking functionalfor restoring the responsiveness of tolerant T cells, we
performed experiments with neutralizing antibodies Stat3 in macrophages, the in vivo response to a tolero-
genic dose of peptide is T cell priming rather than T cellspecific for the inflammatory mediators produced by
LPS-stimulated Stat3/ PEM (Figure 6B). Specific tolerance. This effect of Stat3 deficiency unveiled, there-
fore, a previously unknown role for this signaling path-blockade of either IL-12 (Figure 7C) or RANTES (Figure
7D) partially diminished the positive effect of Stat3/ way in the induction of antigen-specific T cell tolerance.
The findings that PEM with a targeted disruption ofsupernatants upon tolerant T cells. More importantly,
the concurrent blockade of these two inflammatory me- Stat3 have a constitutively activated phenotype and are
more prone to producing inflammatory mediators in re-diators abrogates almost completely the ability of
Stat3/ supernatants to break T cell anergy (Figure 7E). sponse to LPS point to Stat3 signaling as a negative
regulatory pathway in these cells. Interestingly, PEMTherefore, IL-12 and RANTES produced by Stat3/
PEM play a dominant role in restoring the respon- devoid of Stat3 display increased Stat1:1 homodimers
(Figure 4C), a functionally active complex that positivelysiveness of tolerant CD4 T cells.
regulates genes encoding inflammatory factors (Ra-
mana et al., 2000). Previous studies have demonstratedDiscussion
a frequent coactivation of Stat1 and Stat3 by the same
ligand (Bromberg and Darnell, 2000), leading to forma-It is now becoming clear that antigen encounter in the
periphery by cells of the immune system does not al- tion of Stat1:Stat3 heterodimers that may have a higher
association constant than the Stat1:Stat1 homodimericways lead to immune activation and can result instead
in immunologic unresponsiveness (Kearney et al., 1994; complex (Kotenko and Pestka, 2000). It is plausible,
therefore, that Stat3 activation in APCs, by binding acti-Pardoll, 2001). APCs lie at the center of this critical
decision of the immune system, since these cells have vated Stat1, may control the formation of functionally
active Stat1:Stat1 homodimers, thus limiting the magni-been shown to capture antigens in the periphery, mi-
grate to the lymphoid organs, and present processed tude and/or intensity of an inflammatory response. Per-
haps, only in those scenarios when the level of Stat1peptides to T cells in a way that may lead to either
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Figure 7. IL-12 and RANTES Produced by Stat3/ PEM Breaks CD4 T Cell Tolerance
PEM (1  105 cells/well) from Stat3/ mice or controls were stimulated with LPS (5 g/ml) for 24 hr. Then supernatants were collected,
centrifuged, and stored at 70	C.
(A) Supernatants were thawed, and 50 l was added to tolerant anti-OVA CD4 T cells cultured with syngeneic PEM and 3 g/ml of OVA
peptide. Forty-eight hours later, supernatants were collected and assayed for IFN- production by ELISA.
(B) Tolerized AE.7 CD4 T cells (5  104 cells/well) were cultured with 1  105 PEM from B10.BR mice in the presence (or not) of 50 l of the
supernatants described above and specific PCC peptide (1 M). After 48 hr, supernatants were collected and assayed for IL-2 production by
ELISA. Production of IL-2 by nonanergized AE.7 CD4 T cells is displayed as Control.
(C–E) In additional experiments, supernatants from LPS-stimulated PEM were thawed and treated with either (C) anti-IL-12 neutralizing
antibodies (R&D systems), (D) anti-RANTES neutralizing antibodies (R&D systems), or a combination of anti-IL-12 plus anti-RANTES (E) as
well as their respective isotype controls. Untreated or treated supernatants (50 l) were then added to tolerant CD4 T cells cultured with
fresh PEM in the presence or not of specific peptide. Forty-eight hours later, supernatants were collected and assayed for IFN- production
by ELISA. Data represent mean  SE of triplicate cultures and are representative of two independent experiments with similar results.
exceeds the level of activated Stat3 or when Stat3 sig- studies have demonstrated that binding of activated
Stat3 to the IL-10 promoter is required for efficient ex-naling is disrupted, Stat1 homodimers may trigger the
downstream signals that APCs need to efficiently acti- pression of the IL-10 gene (Benkhart et al., 2000). Impor-
tantly, IL-10 has been shown to downregulate the ex-vate T cells.
An additional important feature of Stat3/ PEM is pression of cytokines and costimulatory molecules in
activated APCs (Ding et al., 1993). Furthermore, thistheir lack of production of IL-10 (Figure 6D). Previous
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cytokine has been implicated in the induction of T cell rophages (Figure 6A), together with their enhanced abil-
ity to produce inflammatory mediators (Figure 6B), mayanergy (Groux et al., 1996). Therefore, it is plausible that
the absence of the inhibitory effects of IL-10 may explain render these cells quite efficient professional APCs ca-
pable of presenting the tolerogenic peptide in the appro-the constitutive inflammatory phenotype of Stat3/
PEM and their ability to induce T cell priming rather than priate inflammatory context leading to T cell priming
rather than T cell tolerance in vivo. Alternatively, macro-T cell tolerance. However, different lines of evidence
suggest that the phenotypic and functional changes in phages devoid of Stat3 may provide the inflammatory
microenvironment in which other APCs, such as DCs,Stat3/ PEM may not just be the result of lack of IL-10
production by these APCs. First, similar to our findings could be fully activated to efficiently present HA-peptide
in vivo in a way that resulted in CD4 T cell priming ratherin PEM devoid of Stat3, alveolar macrophages from IL-
10/ mutant mice display increased expression of B7.1 than unresponsiveness. In support of this possibility, we
have recently found an increased population of CD11c,and B7.2 costimulatory molecules (Soltys et al., 2002).
However, while no changes in the expression of MHC CD8 DCs expressing high levels of MHC class II in
the spleen as well as in the lymph nodes of LysMcre/class II molecules are observed in macrophages devoid
of IL-10, a significant increase in the expression of MHC Stat3flox/ mice (data not shown). Although the pheno-
type of these DCs could be just the result of the adjuvantclass II molecules is a characteristic of macrophages
devoid of Stat3 (Figure 6A). Second, recent studies have effect provided by Stat3/ macrophages, it is also pos-
sible that this specific DC subpopulation may havefound that pathways other than IL-10 signaling, such as
NF-
B activation by Toll-like receptors, M-CSF signal- floxed out the Stat3 gene, indicative that they have
passed through a developmental stage in which theing, and NADPH oxidase function, which are also nega-
tively regulated by Stat3, may play a more important LysM promoter is active. Alternatively, perhaps Stat3
signaling represents an important checkpoint limitingrole in the enhanced innate immunity observed in mice
with disruption of this signaling pathway (Welte et al., the differentiation/maturation of myeloid cells, and
therefore, in its absence some monocyte/macrophages2003).
It is interesting that Stat3/ PEM share more pheno- may become CD11c, CD8 DCs. Of note, such an
expansion of DCs expressing high levels of MHC classtypic and functional characteristics with macrophages
from mice lacking the inhibitory Tyro-3 family of receptor II molecules was restricted to myeloid DCs, since no
changes were observed in CD11c, CD8 DCs isolatedtyrosine kinase, Tyro-3, Axl, and Mer (TAM) (Lu and
Lemke, 2001). Freshly isolated macrophages from TAM from the lymphoid organs of LysMcre/Stat3flox/ mice
(data not shown).mice display increased expression of MHC class II mole-
cules, produced elevated amounts of IL-12, and induce In the immune response to self-antigens expressed
in peripheral tissues, host’s APCs capture apoptotic cel-strong lymphocyte activation, reminiscent of our find-
ings in Stat 3/ PEM. It is noteworthy, however, that lular fragments and then migrate to the T cell zone of
secondary lymphoid organs for presentation of peptidewhile genetic disruption of all three inhibitory Tyr-3 re-
ceptors (triple mutant mice) is required to generate in- antigens to antigen-specific T cells. In the absence of
inflammatory signals, this process has been proposedflammatory macrophages, a similar outcome can be
achieved by just disrupting Stat3 signaling pathway in to play a critical role in the induction and maintenance
of peripheral tolerance to self-antigens (Steinman et al.,these cells. The common findings in macrophages from
Stat3/ mice and IL-10/ mice, as well as in TAM triple 2003). Noninflammatory APCs, by having low levels of
MHC, costimulatory molecules, and other adhesion mol-mutant mice, raise the interesting possibility that Stat3
may represent a common signaling pathway linking dif- ecules that participate in T cell priming induce instead
T cell unresponsiveness, a default outcome that typifiesferent inhibitory receptors with their downstream intra-
cellular targets. It is plausible, therefore, that the acti- how the immune system normally responds to antigens
expressed in the periphery. In mice devoid of Stat3 sig-vated phenotype of Stat3/ PEM could be related not
only to their lack of IL-10 production but also to the naling, however, this default response toward tolerance
induction seems to be significantly altered. The proin-enhanced activity of different proinflammatory path-
ways tightly regulated by an intact Stat3 signaling in flammatory phenotype displayed by APCs in these mice
converted a T cell encounter with antigen/APC from athese APCs. Although our in vitro studies have identified
IL-12 and RANTES as important inflammatory signals tolerizing event into a priming event. Furthermore, the
demonstrated ability of Stat 3/ APCs to promote T cellby which Stat3/ PEM can overcome T cell tolerance,
the potential role of overactivated proinflammatory sig- priming and cell-mediated immunity rather than T cell
tolerance provides an explanation to earlier observa-naling pathways (i.e., Stat1 signaling, among others) in
the generation of these inflammatory mediators, how- tions of increased incidence of autoimmune inflamma-
tory bowel disease in mice with targeted disruption ofever, remains to be elucidated.
A previously unknown role for Stat3 signaling in influ- Stat3 in macrophages (Takeda et al., 1999) as well as
in mice with disruption of this signaling pathway in allencing antigen-specific T cell responses in vivo was
uncovered by our findings that in mice with a genetic hematopoietic cells (Welte et al., 2003).
Given the central role of bone marrow-derived APCsdisruption of Stat3 in macrophages, the response to a
tolerogenic dose of peptide is T cell priming rather that in the induction of tolerance to tumor antigens (Soto-
mayor et al., 2001), defining the signaling mechanismsT cell tolerance (Figure 5). It was surprising, that just by
disrupting the Stat3 signaling pathway predominantly by which these cells induce unresponsiveness rather
than activation of T cells is critical for the continuedin one APC subpopulation, such a dramatic effect in
T cell responses could be observed. It is possible that development of effective immune-enhancing therapeu-
tic strategies. Our demonstration that disruption of Stat3the constitutively activated phenotype of Stat3/ mac-
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Antigen Presentation Studiessignaling in either macrophages (Figures 1C and 4B) or
PEM (1  105/well) or BM-derived DCs (1  104/well) were culturedbone marrow-derived DCs (Figure 2B) renders these
with 5  104 CD4 T cells in the presence or not of cognate peptideAPCs capable of restoring the responsiveness of toler-
(either synthetic HA-peptide110-120 SFERFEIFPKE or OVA peptide323-339,ant T cells from tumor-bearing mice has, therefore, im- ISQAVHAAHAEINEAGR). After 72 hr, cells were pulsed with
portant implications for cancer immunotherapy. [3H]thymidine (1 Ci/well, NEN Life Science, MA). Eighteen hours
later, cells were harvested with a Packard Micromate cell harvester.Taken together, our results establish a novel role for
Thymidine incorporation into DNA was measured as counts perStat3 signaling in APC function and regulation of T cell
minute (cpm) in the peptide-pulsed group minus cpm from cellsresponses. Strategies to manipulate Stat3 signaling in
cultured in medium alone divided by the number of clonotypeeither direction (blockade or stimulation) may be able,
T cells in the wells as determined by FACS. In a parallel plate,
therefore, to influence immune activation versus im- supernatants were collected at different time points (24–72 hr) and
mune tolerance, a critical decision with profound impli- stored at 70	C until assayed for IL-2 and IFN- production by
ELISA (R&D Systems, Minneapolis, MN). Values for T cells culturedcations in autoimmunity, transplantation, and cancer im-
in media alone are usually less than 10% of the values for antigen-munotherapy.
stimulated T cells. Data are expressed as the amount of cytokine
produced by 100 clonotype T cells/well.
Experimental Procedures
Mice Nuclear Extracts and Electrophoretic Mobility Shift Assay
Six- to eight-week-old BALB/c, C57BL/6, and B10.BR mice were APCs were treated with LPS (5 mcg/ml) and/or increasing concen-
obtained from the NIH (Frederick, MD). Stat3flox/, LysMcre/Stat3/, trations of the JAK-selective inhibitor, tyrphostin AG490 (Meydan
and LysMcre/Stat3/ mice (H-2b) were provided by Dr. S. Akira et al., 1996) or IL-10 alone before isolation of nuclei. Nuclear extracts
(Osaka University, Japan). LysMcre/Stat3/ mice were mated with were prepared and electrophoretic mobility shift assay (EMSA) de-
Stat3flox/ mice to generate LysMcre/Stat3flox/ mice (experimental termination was performed as previously described (Catlett-Falcone
group). LysMcre/Stat3flox/ from these crosses were used as lit- et al., 1999).
termate controls. TCR transgenic mice expressing an  TCR spe-
cific for peptide 323–339 from ovalbumin (OVA) presented by MHC
RNA Isolation and RNase Protection Assaysclass II, I-Ab (Barnden et al., 1998) were provided by Dr. W. Heath
Total RNA was isolated from PEM by TRIzol reagent (Life Technolo-(The Walter and Eliza Hall Institute, Australia). All the experiments
gies, Inc., Grand Island, NY). RNase protection assays (RPAs) wereinvolving the use of mice were performed in accordance with proto-
carried out using the PharMingen’s cytokine and chemokinecols approved by the Animal Care and Use Committees of the Uni-
multiprobe templates according to the manufacturer’s protocol.versity of South Florida.
Tolerance ModelsCell Lines
The following experimental models were utilized.A20 lymphoma cells expressing HA as a model tumor antigen were
Tumor-Induced Antigen-Specific T Cell Toleranceselected and grown in vitro as previously reported (Staveley-O’Car-
In brief, 2.5  106 CD4 anti-HA transgenic T cells were injected i.v.roll et al., 1998). B16 melanoma cells transfected with ovalbumin
into tumor-free mice or A20HA-bearing mice. Twenty-one days after(B16-OVA) were provided by Dr. P. Dellabona (Instituto San Rafaelle,
T cell transfer, animals were sacrificed and T cells were reisolatedMilan, Italy). For in vivo tumor challenge experiments, tumor cells
from their spleens as previously described (Staveley-O’Carroll etwere washed in HBSS and injected via the tail vein (A20HA) or s.c.
al., 1998). To determine the percent of isolated anti-HA clonotypic(B16-OVA) into BALB/c or C57BL/6 mice, respectively, in a total
CD4 T cells, purified T cells were stained with FITC-conjugatedvolume of 0.2 ml, 1  106 tumor cells per mouse.
goat anti-mouse CD4 (Caltag, Burlingame, CA) and biotinylated ratThe dendritic cell line, DC 2.4 (Shen et al., 1997), kindly provided
anti-clonotypic TCR antibody mAb 6.5 followed by PE-conjugatedby Dr. K. Rock (University of Massachusetts), and BM-derived DCs
streptavidine (Caltag). For this analysis, 50,000 gated events werewere transiently transfected with either pcDNA3 empty vector or
collected on a FACScan and analyzed using Flow-Jo software. Anti-Stat3c expression vector (Bromberg et al., 1999) using Lipofecta-
gen-specific proliferation and cytokine production by clonotypicmine methods (InVitrogen, Carlsbad, CA). Transfection efficiency
CD4 T cells in response to HA-peptide presented by APCs waswas between 10%–15% for DC 2.4 cells and 10% for bone marrow-
determined as described above. For induction of antigen-specificderived DCs.
T cell tolerance in H-2b tumor-bearing mice, a similar experimental
approach was utilized, the only difference being that 1  106 anti-
Isolation of Peritoneal Elicited Macrophages OVA CD4 transgenic T cells (OT-II) were transferred i.v. into tumor-
Mice were injected intraperitoneally (i.p.) with 1 ml of thyoglicollate free or animals bearing an OVA-expressing tumor (B16OVA). Four-
(DIFCO Laboratories, Detroit, MI). Four days later, PEM were ob- teen days after T cell transfer, animals were sacrificed and OT-II
tained by peritoneal lavage. MHC class II expression (I-Ab) on PEM cells were reisolated from their spleens. The percent of anti-OVA
was determined by staining with a FITC-conjugated AF6-120.1 anti- transgenic CD4 T cells (OT-II) was determined by staining with
body (BD Pharmingen, San Diego, CA). The expression of B7.1 and Cychrome-conjugated anti-mouse CD4 (BD, Pharmingen), anti-V2-
B7.2 molecules was determined by staining with either a FITC-conju- PE and V5-FITC conjugated monoclonal antibodies (BD, Phar-
gated anti-CD80 or a FITC-conjugated anti-CD86 (BD Pharmingen) mingen).
MoAbs. Ten thousand gated events were collected on a FACScan High Dose Peptide Model
(Becton Dickinson, San Jose, CA) and analyzed using Flow-Jo soft- In brief, 2.5  106 anti-HA/I-Ed TCR transgenic T cells were trans-
ware (Treestar Inc). ferred into BALB/c mice, littermates, or LysMcre/Stat3flox/ mutant
mice (backcrossed for ten generations to H-2d background). Two
days later, half the mice were injected i.v. with a tolerogenic doseGeneration of Bone Marrow-Derived DCs
In brief, DCs were generated from murine bone marrows using RPMI of HA-peptide110-120 (275 mcg), and 2 weeks later all the animals were
sacrificed. T cells from the spleen of these animals were isolated,1640 medium supplemented with 10% FCS, 20 ng/ml murine recom-
binant GM-CSF, and 10 ng/ml IL-4 (both from RDI, Flanders, NJ). and their phenotypic and functional characteristics were analyzed
as described above.The cultures were maintained at 37	C in 5% CO2 humidified atmo-
sphere in 24-well plates. On day 3 of culture, floating cells were In Vitro Induction of CD4 T Cell Tolerance
AE.7 CD4 T cells were stimulated for 5 days with anti-CD3 antibodygently removed and fresh medium with cytokines was replaced. On
day 5, cells were collected, and DCs were enriched by centrifugation in the absence of costimulation. As positive control, AE.7 CD4
T cells were stimulated with anti-CD3 plus anti-CD28 antibodies asover a 13.5% metrizamide gradient (Accurate Chemicals, West-
bury, NY). previously described (Jenkins et al., 1990).
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